M. R. A. KHAIRI, M.D.; R. D. ALTMAN, M.D., F.A.C.P.; G. P. DeROSA, M.D.; J. ZIMMERMANN, M.D.; R. K. SCHENK, M.D.; C. C. JOHNSTON, M.D., F.A.C.P.
Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight day for 6 to 24 months. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 months of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight day. In patients treated with 10 or 20 mg of EHDP/kg body weight day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight day but not in those receiving 5 mg/kg body weight day. Five milligrams of EHDP/kg body weight day was effective and appears to be safer than the higher doses.
KHAIRI MRA, ALTMAN RD, DeROSA GP, ZIMMERMANN J, SCHENK RK, JOHNSTON CC. Sodium Etidronate in the Treatment of Paget's Disease of Bone: A Study of Long-Term Results. Ann Intern Med. ;87:656–663. doi: 10.7326/0003-4819-87-6-656
Download citation file:
Published: Ann Intern Med. 1977;87(6):656-663.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use